1. Home
  2. BDJ vs PGEN Comparison

BDJ vs PGEN Comparison

Compare BDJ & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Enhanced Equity Dividend Trust

BDJ

Blackrock Enhanced Equity Dividend Trust

HOLD

Current Price

$9.73

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$5.18

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDJ
PGEN
Founded
2005
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
BDJ
PGEN
Price
$9.73
$5.18
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.33
AVG Volume (30 Days)
581.4K
5.3M
Earning Date
01-01-0001
05-13-2026
Dividend Yield
8.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$230,981,000.00
Revenue This Year
N/A
$1,115.92
Revenue Next Year
N/A
$81.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.42
$1.47
52 Week High
$9.76
$6.04

Technical Indicators

Market Signals
Indicator
BDJ
PGEN
Relative Strength Index (RSI) 68.88 51.97
Support Level $9.05 $3.90
Resistance Level N/A $5.47
Average True Range (ATR) 0.09 0.33
MACD 0.01 -0.08
Stochastic Oscillator 100.00 16.83

Price Performance

Historical Comparison
BDJ
PGEN

About BDJ Blackrock Enhanced Equity Dividend Trust

BlackRock Enhanced Equity Dividend Trust is a closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option to enhance distributions to its shareholders.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: